What is the recommended management for sinus tarsi syndrome?

Sinus Tarsi Syndrome Management

For sinus tarsi syndrome, initial management should consist of conservative treatment including corticosteroid injections into the sinus tarsi, which provide effective short-term relief, followed by arthroscopic debridement if symptoms persist beyond 3-6 months of conservative therapy.

Initial Conservative Management (First-Line)

Conservative treatment should be attempted first for all patients with sinus tarsi syndrome:

• Corticosteroid injections (compound betamethasone 1 ml + lidocaine 4 ml) into the sinus tarsi provide significant pain relief and functional improvement 1, 2
• Expected outcomes: VAS scores improve from ~8 to ~1-2 within the first month 1
• Critical caveat: 65% of patients experience symptom recurrence within 12 months 1
• Alternative injection options include platelet-rich plasma (PRP) or ozone, which show similar 6-month outcomes to corticosteroids 2

Duration of conservative trial: 3-6 months before considering surgical intervention 1, 3

Surgical Management (When Conservative Treatment Fails)

Stage 1: Arthroscopic Debridement

When to proceed: Persistent symptoms after 3-6 months of failed conservative treatment 4, 1, 3

The first surgical intervention should be arthroscopic subtalar joint debridement with removal of:

• Fibrotic tissue remnants
• Inflamed synovium
• Scar tissue within the sinus tarsi 4

Success rate: Approximately 58% (52/89 patients) achieve lasting remission after debridement alone 3

Stage 2: Address Underlying Pathology (If Debridement Fails)

For the 42% who fail initial debridement, identify and treat the specific underlying cause 3:

1. Subtalar instability (most common recurrence cause):

   • Perform lateral ankle ligament reconstruction
   • Success rate: 26% (5/19) with ligament reconstruction alone 3
   • Important: If chronic ankle instability is present initially, combine debridement with ankle stabilization at first surgery 5

2. Tarsal coalition:

   • Resection of talocalcaneal bridge
   • Success rate: 50% (5/10) 3

3. Neurological involvement:

   • Nerve release surgery for severe neurological signs
   • Success rate: 50% (2/4) 3

Stage 3: Subtalar Arthrodesis (Definitive Treatment)

Indications:

• Failed soft tissue procedures
• Peroneal spastic flatfoot
• Persistent peroneal spasm after previous surgeries 3

This achieves satisfactory results in all remaining cases, with AOFAS scores improving from 35 to 86 3

Key Clinical Pearls

Anatomical consideration: 93% of patients have an arch structure between posterior and middle subtalar joints that may contribute to pathomechanics 5

Radiographic risk factors: Patients with steeper sinus tarsi morphology (greater depth-to-length ratio) are at higher risk and may benefit from earlier surgical consideration 6

Staged approach rationale: 67% (184/273) of patients ultimately require surgical management, but starting with less invasive procedures allows appropriate patient selection for more extensive surgery 3

Common Pitfalls to Avoid

• Don't perform arthrodesis first: Always attempt soft tissue procedures before fusion, as 58% achieve lasting relief with debridement alone 3
• Don't ignore ankle instability: If chronic ankle instability coexists, address it simultaneously with debridement to prevent recurrence 5
• Don't abandon treatment after failed injections: The 65% recurrence rate with injections doesn't predict surgical failure—arthroscopic treatment remains highly effective 1, 3